Chronic hepatitis B virus (HBV) infection is the major cause of hepatocellular carcinoma (HCC). The pre-S 2 mutant large HBV surface antigen (LHBS) is highly associated with HCC. This study analyzed the expression of the large form of surface protein in tumors and evaluated the LHBS with mutations within the pre-S 2 region as a high-risk recurrence marker in HCC patients after curative hepatic resection. By analyses using immunohistochemical staining (n 5 12) and western blotting (n 5 22), the HBV surface protein, which is mainly comprised of the major form of HBV surface antigen, was greatly diminished in the tumors. However, LHBS was not significantly decreased in tumorous regions, suggesting that LHBS maintains its expression in cancer development. A cohort of 175 patients with HBV-related HCC who underwent curative hepatic resection was analyzed for pre-S gene mutations using Pre-S Gene Chip. Results of the multivariate regression analysis showed that the serum pre-S 2 mutant level and the American Joint Committee on Cancer stage were the two main independent high-risk factors for recurrence. A Cox proportional hazards analysis also revealed a prediction model, which indicated the recurrence-free survival rate along with the time after surgery; this was developed and further validated in an independent HCC cohort. Receiver operating characteristic curve analysis revealed that the model showed close sensitivities in the main and validation cohorts (area under the curve values, 0.741 and 0.704, respectively). Conclusion: Unlike the major HBV surface antigen, LHBS is mostly expressed in the tumorous regions of HBV-induced HCC, indicating that it plays a unique role in tumor progression; the relative level of pre-S 2 mutant in serum is, independently of tumor stage, an important high-risk marker for HCC recurrence after primary hepatic resection. (HEPATOLOGY 2018; 68:815-826).
H epatocellular carcinoma (HCC) is the most frequent visceral neoplasm worldwide and among the top causes of cancer mortality. (1, 2) High HCC tumor recurrence rates after curative hepatic resection cause poor prognosis; therefore, longterm monitoring of HCC progression after primary treatment is important. So far, effective and reliable high-risk biomarkers for HCC progression have not been identified. The glycoprotein a-fetoprotein (AFP) is the most common serum marker to detect and follow up HCC. However, approximately one third of patients with chronic hepatitis or cirrhosis present with raised AFP levels, whereas similar ratios of HCC patients present with normal AFP levels at the time of HCC diagnosis and usually remain low in progression into advanced stages. (3, 4) Chronic hepatitis B virus (HBV) infection is a major cause of HCC and plays a critical role in its progression. (5) (6) (7) (8) Antiviral therapies have been shown to be beneficial to HCC prognosis after primary cancer treatments such as surgery, radiofrequency ablation, and transarterial chemoembolization, (9) (10) (11) which suggests that viral factors are consistent oncogenic players in multiple stages of HCC development. Therefore, it is important to identify high-risk HBV markers that must be frequently followed up and evaluated when considering prophylactic therapies. Some studies (12) (13) (14) have reported that hepatitis B x (HBx) gene mutations and surface antigen levels are correlated with the prognosis of HCC and that the underlying molecular mechanisms are not clear. Previous studies using immunohistochemical (IHC) analysis have documented that the HBV surface protein was greatly diminished in cancerous regions, suggesting that the HBV surface antigen (HBS) promoter is down-regulated in the tumor. (15, 16) However, the large HBS (LHBS) protein, which is the translational product of the 2.4-kb pre-S 1 surface gene transcript and is under the control of a different promotor from the major HBS gene, has not been extensively examined in tumorous regions. It has been reported that LHBS induced HCC in transgenic mice, suggesting that it plays a unique role in carcinogenesis; and its expression levels in tumors remained to be examined. (17) In addition, the LHBS pre-S 2 mutant, partially deleted in the pre-S 2 region of the HBS gene, has been highly associated with HBVrelated HCC. (18) Pathology test findings have demonstrated that pre-S 2 mutant LHBS is associated with the histological morphology of the type II ground glass hepatocyte (GGH), characterized by a clustered nodule formation and a growth advantage, unlike type I GGH, which often harbors partial deletions in the pre-S 1 region and usually singly scatters in the livers of HBV carriers. Type II GGH has therefore been hypothesized as a preneoplastic change in chronic carriers and in the peritumorous regions of HCC. (18, 19) We also recently reported that clustered type II GGHs in HCC are correlated with higher tumor recurrence rates in patients who underwent a hepatic resection, which indicates that the pre-S 2 mutant LHBS is important for HCC progression. (20) Other studies (21, 22) have also reported that HBV carriers who presented with pre-S 2 mutant LHBS in serum were predisposed to advanced liver diseases, including liver cirrhosis and HCC. Taken together, these findings have proposed that pre-S 2 mutant LHBS is a high-risk biomarker for HCC in chronic HBV carriers and for HCC recurrence after a hepatic resection.
Pre-S 2 mutant LHBS, which is prevalent in the late phase of HBV chronic infection and HCC, presents with high relevance for liver carcinogenesis. (22, 23) Due to mutation-induced protein misfolding, it accumulates in the endoplasmic reticulum (ER) and triggers ER stress-dependent DNA damage, cyclin A overexpression, and vascular endothelial growth factor activation, all of which eventually lead to genomic instability and angiogenesis. (24) (25) (26) (27) Pre-S 2 mutant LHBS protein also directly interacts with c-Jun activation domain-binding protein 1, which degrades cyclin-dependent kinase inhibitor p27 Kip1 and, consequently, G 1 -Sphase cell-cycle progression, even in the presence of DNA damage. (28) We also recently reported (29) that pre-S 2 mutant LHBS transgenic mice were genomically unstable, which was indicated by global gene copy number variations significantly higher than those in agematched HBx mice. This indicates that the pre-S 2 mutant LHBS is the main viral oncoprotein which induces host genomic instability and triggers carcinogenesis.
Given that the pre-S 2 mutant LHBS plays an important role in hepatocellular carcinogenesis, we hypothesized that the large form of HBS expresses in HCC. We also hypothesized that detecting the pre-S 2 mutant LHBS in serum, the most accessible specimen for examining HBV infection, is useful for evaluating the relative risks of tumor recurrence in HCC patients. To conveniently detect the pre-S mutant HBS gene in serum and cells, we recently developed the pre-S gene chip, which provides a much faster and more sensitive approach than direct DNA sequencing in terms of detecting pre-S mutations. (30) Using this method, we performed semiquantitative measurement of the pre-S gene deletions in the serum of HCC patients who had undergone a hepatic resection. We found that the pre-S 2 mutant LHBS level in serum was highly correlated with HCC recurrence.
Materials and Methods

HCC STUDY COHORTS
The main study cohort included 207 patients who had undergone a hepatic resection for HCC at the National Cheng Kung University Hospital (NCKUH) between December 2005 and August 2014 (Fig. 1) . All HCC cases were diagnosed by medical imaging evaluation and biopsy histopathologic reviews by two pathologists independently. The tumor/node/metastasis staging, fibrosis scoring, and histologic grading followed the American Joint Committee on Cancer (AJCC) classification. (31) Liver cirrhosis in the nontumorous liver was observed with hematoxylin and eosin and Masson's trichrome staining. The severity of fibrosis was staged according to the Ishak fibrosis scoring system (stages 0-6). (32) All of the patients provided signed informed consent to use their blood and surgical specimens for this research. All of the protocols for this study were reviewed and approved by the NCKUH institutional review board (no. ER-100-058 [04/25/2011]). The patients were regularly followed up at clinic visits every 1-3 months after a hepatic resection. Those who were coinfected with HBV and hepatitis C virus and those who were lost to follow-up for more than 6 months were excluded. For the remaining 175 cases, there were 134 (77%) men and 41 (23%) women (mean age, 56.2 years; range, 22-81 years), and 61% (107/175) of them received nucleotide/nucleoside analog antiviral treatments prior to surgery ( Table 1 ). The second study cohort, which was used to validate the statistical findings in the NCKUH patients, contained 55 patients who had undergone a hepatic resection at Chi Mei Medical Center between October 2012 and August 2014. The patients were regularly followed up for clinical outcomes as described for the NCKUH cohort (Supporting Table S1 ).
IHC ANALYSIS OF GGH LIVER TISSUES
IHC (n 5 12) was performed on 5-lm-thick formalin-fixed, paraffin-embedded sections. The anti-HBS antibody (clone T9; Thermo Fisher Scientific), which recognized the major HBS region, and the inhouse developed anti-LHBS antibody, which recognized the pre-S 1 region, were used as the primary antibodies. The protocol of the IHC staining analysis followed that described. (20) Briefly, the procedures were done with the Benchmark XT autostainer (Ventana Medical Systems Inc.). Deparaffinized sections were incubated with the primary antibody at room temperature for 30 minutes. Subsequently, the sections were visualized by an aminoethyl carbazole substrate kit (Zymed Laboratory, Inc.). Counterstaining was carried out with hematoxylin. GGH patterns in the nontumorous regions of liver parenchyma were classified as follows: type I GGH was identified by a strong, globular, or "inclusion-like" staining pattern; type II GGH was identified by dense surface antigen staining at the cell margin or periphery. (25) The percentage of positively staining cells in the nontumorous and tumorous regions was determined.
WESTERN BLOTTING OF LHBS IN HCC TISSUES
Snap-frozen protein lysates of the surgically resected tumorous and peritumorous HCC tissues of patients (n 5 22) at NCKUH were analyzed for LHBS expression by western blotting, following the protocol described. (29) The wild-type (n 5 10) and pre-S 2 mutant (n 5 12) cases were preidentified by pre-S gene chip analysis. (30) LHBS was detected using an inhouse-developed mouse monoclonal antibody (clone 7-21-5) recognizing the pre-S 1 region. To confirm the specific recognition of the antibody to LHBS, human kidney 293T cells, which did not endogenously express HBS, were transfected with the wild-type, pre-S 1 mutant and pre-S 2 mutant LHBS genes and analyzed by western blotting.
PRE-S GENE CHIP ANALYSIS TO SEMIQUANTITATIVELY DETECT PRE-S DELETION MUTANTS
Protocols for the PCR to amplify the HBV pre-S region gene and for the pre-S gene chip analysis followed that described. (30) Briefly, viral DNA in the serum and liver tissues of HCC patients was extracted using an automated viral DNA extraction system (Taigen Bioscience). The pre-S region was amplified using the following PCR primers: forward, 5
0 -GCG GGTCACCATATTCTTGGG-3 0 , and reverse, 5 0 -GAGTCTAGACTCTGCGGTAT-3 0 . The PCR products were directed to TA cloning (Invitrogen). Multiple plasmid clones were then analyzed using colony PCR with 5 0 -digoxigenin-labeled M13 primers, which were derived from the cloning vector. These PCR products were then analyzed using the pre-S gene chip, which was 7 mm (height) 3 10 mm (width) and contained 42 oligonucleotide probes spanning the pre-S regions. After hybridization of the digoxigeninlabeled pre-S LHBS PCR products to the probes on the chip, the chips were mixed with the antidigoxigenin-alkaline phosphatase Fab fragments (Roche), then incubated with the alkaline phosphatase substrates nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate for signal development. The pre-S deletion mutants, which revealed no hybridization signals in some pre-S region probes, were identified. In this study, to semiquantitatively detect pre-S deletion mutants, 30 independent pre-S clones in each serum sample were analyzed.
DETECTION OF HBV MARKERS
HBV viral loads were determined using the COBAS TaqMan HBV Test (v2.0; Roche Diagnostics, Pleasanton, CA). Hepatitis B e antibody, hepatitis B e antigen, and hepatitis B surface antigen quantitation were measured using Abbott Architect Analyzers (Abbott Diagnostics, Abbott Park, IL). HBV genotypes in serum were determined using multiplex PCR, as described. (33) 
MULTIVARIATE REGRESSION AND COX PROPORTIONAL HAZARDS STATISTICAL ANALYSES
The associations of pre-S deletion percentages and HCC recurrence were analyzed using a Mann-Whitney test. Univariate logistic regression analysis was used to screen the clinicopathologic factors correlated with HCC recurrence. Factors with P < 0.2 in univariate analysis were retained for multivariate regression analysis. (34) The recurrence-free (Recurrence
2
) and overall survival curves of the pre-S 2 mutant surface gene were calculated using the Kaplan-Meier method. The effects of serum pre-S 2 mutant levels (<0.05 versus 0.05) on the relative risks of recurrence among the same AJCC groups were analyzed using Fisher's exact test. Finally, the HCC recurrence probabilities for different situations of pre-S 2 mutants and AJCC stages were then estimated, based on Cox proportional hazards analyses. The tumor AJCC stages were divided into stages S1-S3, and the serum pre-S 2 mutant levels into P1 (pre-S 2 mutant < 0.05), P2 (0.05 pre-S 2 < 0.15), and P3 (pre-S 2 0.15). The risk scores of the nine combinations of AJCC stage and pre-S 2 mutant level were computed, and Cox survival curves were developed.
Results
To explore the expression of the LHBS in HCC, tumors surgically resected from the HBV-related HCC patients were analyzed by IHC staining, using the antibodies specifically recognizing the pre-S 1 or major S regions. The results showed that the staining signals detected by the HBS antibody, which mainly detects the major (i.e., small) surface protein, were dramatically lower in the tumorous regions than the peritumorous regions, where the HBS signals were usually intense, suggesting that the HBS gene promoter was down-regulated in the process of carcinogenesis. (35) However, in the IHC analysis using the pre-S 1 region monoclonal antibody, which specifically detected LHBS, the tumorous regions, similar to the nontumorous regions, presented with strong staining signals ( Fig. 2A,B) . By western blotting using the pre-S1 region monoclonal antibody, it was found that 95% (21/22) of HCC cases presented with positive LHBS signals in both tumorous and peritumorous regions, and as low as 5% (1/22) presented with LHBS in the peritumorous region only (Fig. 2C) . And wild-type (n 5 10) and pre-S 2 mutant (n 5 12) cases presented similar results. These data clearly demonstrated that, unlike the major HBS, LHBS maintains its continuous expression in carcinogenesis and probably plays an important role in cancer progression.
The pre-S 2 mutant LHBS, which contributes to type II GGH, has been shown to associate with HCC initiation and progression. We explored the potential of pre-S 2 mutant LHBS as a serum biomarker for HCC progression by first detecting the pre-S mutations in sera and livers of these patients using pre-S gene chips. The results showed that most of the pre-S deletions in GGH were seen in the serum of the same HCC patient, indicating that detecting pre-S mutation in the serum can reflect that in GGH and provide a convenient approach for characterizing pre-S deletions in HBV carriers (Supporting Table S2 and Supporting Figs. S1 and S2). Therefore, a cohort of 175 HBVrelated HCC patients who had been admitted to our medical center for a hepatic resection was recruited for the further study. These patients were regularly followed up at clinic visits every 1-3 months for a mean of 45.7 months (range, 6.5-115.6 months). HCC recurred in 100 patients (57.1%) after a mean followup of 15.8 months (range, 1.1-70.7 months) postsurgery, and 41 (23.4%) died of HCC (mean, 25.5 months; range, 6.5-58.1 months) postsurgery. To semiquantitatively detect pre-S deletion mutants in the serum, 30 independent pre-S clones in every patient were analyzed using pre-S gene chip assays: 39% (68/ 175) of the patients with HCC had pre-S gene deletions. HBS genes were partially deleted in the pre-S 1 (17% [30/175] ) and pre-S 2 (31% [55/175]) regions, and some deletions (10% [17/175] ) spanned the pre-S 1 and pre-S 2 regions ( Table 2) . Results of the pre-S deletion analysis by pre-S gene chip were also fully consistent with those by direct DNA sequencing in representative cases tested (14 cases with 24 independent pre-S clones), indicating that the pre-S gene chip is reliable for analyzing pre-S deletions (Supporting Table S3 ). The correlations between HCC recurrence and various clinicopathologic factors were examined. MannWhitney U tests, used to compare the relative levels of pre-S deletion mutants in serum with recurrence rates, showed that pre-S 2 and total pre-S, but not pre-S 1 , mutations had significantly higher levels in the Recurrence 1 group than in the Recurrence 2 group (Fig. 3A,B) . In addition, to focus on patients with significant levels of pre-S mutants, we also examined the association of HCC recurrence with pre-S deletion mutations 5% (2 of 30 clones) of the total HBS clones in serum. Interestingly, patients with 5% pre-S 2 mutants in serum had significantly lower diseasefree and overall survival than did patients with <5% pre-S 2 mutants in serum (Fig. 3C,D; Supporting Fig.  S3 ). Also, results of the multivariate regression analysis showed that of the various viral and clinicopathologic factors analyzed, only the pre-S 2 deletion mutant (5%) and the AJCC stage were correlated with HCC recurrence rates. And unlike those with pre-S 2 deletion mutants, patients with pre-S 1 deletion mutants 5% of the total HBS clones did not show correlation with recurrence (Table 3 ). We also found that among the patients at the same AJCC stages, those with >5% pre-S 2 mutants showed higher odds ratios to HCC recurrence than did those with <5% pre-S 2 mutants in serum, except those in stage 3, where the case number was relatively low (22 cases <5% versus 7 cases 5%) (Table 4) , and the pre-S 2 mutation showed no correlation with AJCC stage (Supporting Fig. S4 ), suggesting that they are two independent important factors contributing to HCC prognosis.
The relative HCC recurrence risks in our posthepatic resection patients were calculated, based on a Cox proportional hazards analysis using the AJCC stage and the serum pre-S 2 mutant level as covariables. The Cox analysis showed that, for patients with tumors at the same AJCC stage, those at pre-S 2 mutant level 3 (0.15) had higher risk scores than did those at pre-S 2 mutant levels 1 (<0.05) and 2 (0.05 3 < 0.15); this applied to all three AJCC tumor stages ( Fig. 4A; Supporting Fig. S5 ). Cox survival curves, which indicated time-related HCC recurrence probabilities in post-hepatic resection patients, were developed (Fig. 4B) . These curves can potentially serve as a convenient way to predict the recurrence risk of HCC patients.
To validate the Cox prediction model developed in the main study cohort, an independent HCC cohort (n 5 55) given the same treatments in another hospital was tested as a validation set (basal characteristics are shown in Supporting Table S1 ). The results of receiver operating characteristic curve analyses in these two cohorts showed that the area under the curve values in the training (i.e., main) (0.741) and validation (0.704) sets were very close (Fig. 4C,D) . This finding demonstrated that the Cox model, which predicts HCC recurrence rates based on AJCC stage and serum pre-S 2 
Discussion
HBV-related HCC remains among the highestmortality cancers worldwide. Local recurrence and metastasis occur at high rates even after patients have received a curative liver resection. Though many highrisk biomarkers for HCC recurrence have been reported, reliable predictive viral markers for it were lacking. So far, nuclear localization of HBx in HCC tissues has been reported to correlate with higher HCC recurrence, probably due to the transcriptional activation of HBx to some oncogenic factors; presence of anti-hepatitis B core antibody has also been found to correlate with HCC recurrence, but the molecular mechanism was not clear. (36, 37) Here we demonstrated that, unlike the major HBS, which dramatically decreases in tumors, the large form of HBS maintains its expression in hepatocytes while progressing into malignancies, supporting the previous findings that LHBS expression was associated with cancer development. (15) (16) (17) In addition, based on the strong association of the type II GGHs harboring the pre-S 2 mutant LHBS oncoprotein with HCC initiation and prognosis, we found that the relative level of pre-S 2 mutant oncogene in serum is an important predictive biomarker for the risk of HCC recurrence. Cox regression analysis showed that serum pre-S 2 mutant levels, combined with the AJCC tumor stage, reliably predicted the risk of HCC recurrence.
Until now, the exact role of LHBS in liver carcinogenesis has not been clearly demonstrated. LHBS, containing the integral pre-S 1 domain mediating the binding of the viral envelope to the receptor sodium taurocholate cotransporting polypeptide on the hepatocyte, is essential for viral infection and the life cycle. (38) Previous studies have documented that overproduction of LHBS in the hepatocyte caused an ER overload response, leading to a profound reduction in small HBS maturation and secretion, which subsequently attenuated host immune surveillance for viruses. (39) It was also reported that LHBS overexpression in transgenic mice initiated HCC, possibly through LHBS-induced necro-inflammatory liver regeneration. (17, 40) The exact pathological effect of sustained expression of LHBS in the carcinogenic process remains to be clearly delineated. Thus, suffice it to say that the pre-S 2 mutant LHBS, which triggers sustainable ER stress response due to mutationinduced protein misfolding, likely plays a significant role in cancer progression.
In this study, taking advantage of the availability of simultaneously analyzing multiple pre-S clones by the pre-S gene chip assay, we performed semiquantitative analysis to detect the relative level of pre-S mutant surface gene in HBV virions secreted to serum, which likely reflected the pre-S gene expression in GGHs. Though the majority of the cases in our cohorts undertook antiviral therapies prior to HCC diagnosis, which dramatically reduced viral titers, it was found that the highly sensitive PCR method allowed us to successfully amplify the pre-S gene in most cases for the pre-S gene chip analysis. And given the high detection rates of pre-S mutant genes in serum, we hypothesize that GGH, prevalent in the peritumorous regions of HCC, accommodates the residual activities of viral replication and that the genome harboring pre-S 2 deletion can be packaged into the viral capsid. Our previous GGH studies (20) showed that the intensity of the type II GGH presenting with clustered staining patterns of HBS in peritumorous regions was associated with HCC recurrence and consequent mortality, which indicated that pre-S 2 mutant LHBS plays a significant role in HCC progression. The findings in this study are consistent with the findings of other studies (20) in that the level of type II GGH harboring pre-S 2 mutant LHBS is critical for determining the risk of HCC recurrence. It also indicates that the serum pre-S 2 mutant surface gene can be used as an easily accessible biomarker for a GGH 1 liver. The relative ratios of pre-S 2 mutant surface gene clones in serum, divided into levels 1-3, are correlated with HCC recurrence, as is the AJCC tumor stage. It is, therefore, conceivable that the relative magnitude of the high-risk versus lowrisk oncogenic factors in cells needs to be assessed in order to sensitively detect the relative risk of HCC progression. In fact, in the long-term follow-up of our HCC cohort, we found some patients for whom the serum pre-S 2 mutant LHBS levels were low when they had their hepatic resection but greatly increased when their HCC recurred (data not shown), which suggests that the serum pre-S 2 mutant LHBS level is correlated with development of HCC progression. Thus, because most of the patients with recurrence received transarterial chemoembolization or systemic chemotherapies or target therapies instead of surgery to remove the recurred tumors, it was very difficult to clarify whether the pre-S mutation clones in the recurred tumors derived from the previously existing tumor cells or the de novo malignant clones. Further comparative clinical studies between the original and recurred tumors characterizing the pre-S mutations as well as other genomic markers would be necessary to fully understand this issue.
Some high-risk biomarkers for HCC recurrence have been established. Most of them are host factors expressed in liver tissue. (41) Two important examples are b-catenin, a well-recognized high-risk marker for HCC recurrence and of its ability to induce the transcription of genes in cell proliferation and stemness, and, c-Myc, which is crucial for HCC oncogenesis and metastasis. (42, 43) Although these factors provide important predictive values for HCC prognosis, they must be directly examined in liver tissue. However, reliable high-risk biomarkers in serum, which is a much more accessible specimen source for HCC recurrence, are still underdeveloped. The promising highrisk markers in serum for HCC recurrence include AFP and des-c-carboxy prothrombin. (44, 45) Thus, although some studies have reported that AFP (>400 IU) was correlated with an increase in the rate of HCC recurrence after a hepatic resection, supportive findings remain to be shown in other study cohorts. (43) In addition, des-c-carboxy prothrombin, the noncarboxylated and nonfunctional form of prothrombin induced by a lack of vitamin K-dependent carboxylase enzyme in many HCC cells, has been recently reported (45) as a more promising high-risk biomarker than was AFP. Nevertheless, we found that the serum HBV pre-S 2 mutant level was a predictive high-risk biomarker for HCC recurrence after a hepatic resection. A reliable Cox model for predicting HCC recurrence risk based on the serum pre-S 2 mutant level combined with the AJCC tumor stage provided a convenient method for determining the prognosis of HCC patients after primary treatments.
In conclusion, we found that, unlike small HBS, LHBS maintains its expression in HCC and likely plays an important role in promoting tumor progression. We also showed that, independently of AJCC tumor stage, the serum pre-S 2 mutant level is an important predictive high-risk marker for HCC recurrence. Additional investigations that combine evaluations of the pre-S 2 mutant level with other serum high-risk markers, e.g., AFP and des-c-carboxy prothrombin, in HCC patients will be an important direction for improving the predictive power for HCC recurrence in patients who have undergone a hepatic resection or other primary treatments. Detecting these multiple high-risk targets should greatly benefit the execution of precision medicine in HCC therapies.
